Novo Nordisk Hails Success in Diabetes Drug Trial
May 22 2015 - 10:58AM
Dow Jones News
LONDON--Danish pharmaceutical company Novo Nordisk A/S
(NOVO-B.KO) Friday said a trial of Saxenda showed treatment with
the drug for three years reduced the risk of developing type 2
diabetes compared with a placebo.
-Write to Rory Gallivan at rory.gallivan@wsj.com; Twitter:
@RoryGallivan
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
Novo Nordisk (NYSE:NVO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Novo Nordisk (NYSE:NVO)
Historical Stock Chart
From Apr 2023 to Apr 2024